<DOC>
	<DOCNO>NCT00725946</DOCNO>
	<brief_summary>This pilot image study woman whose tumor express NIS [ Na+I- symporter , sodium iodide symporter ] . Eligibility limit presence strong ( 3+ ) and/or plasma membrane stain &gt; 20 % cell determine immunohistochemical method . A total 10 patient image 124I PET/CT ( serial scan 24 hour period ) determine radioiodide uptake distribution tumor tissue . Thyroid iodide uptake retention block begin one week prior 124I PET/CT scan thyroid hormone ( T3 ) methimazole ( impedes organification ) . Tumor , organ whole body dosimetry calculate patient .</brief_summary>
	<brief_title>Pilot Study Determine Radioiodide Accumulation Dosimetry Breast Cancers Using 124I PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Stage IIV breast cancer . Patients must clinical radiographic evidence localize metastatic disease . 2 . Criteria NISpositivity define : &gt; = 20 % cell plasma membrane and/or strong intracellular/plasma membrane immunoreactivity 3 . Any previous therapy include radiation therapy allowable . 4 . Women 18 year age old . 5 . Patients must life expectancy least 3 month 6 . Patients ECOG Performance Status 03 eligible . 7 . If chemotherapy , thyroid suppression initiate sooner two week last chemotherapy cycle . 8 . Ability understand willingness sign write informed consent document . 9 . Discontinuation hormonal biological therapy 10 day study prefer mandate . 10 . Laboratory test ( CBC , comprehensive metabolic panel ) must perform within 120 day prior study initiation . 1 . History metastatic thyroid cancer 2 . Exclude use cytotoxic , hormonal biological agent one week prior image . 3 . Pregnant nursing patient exclude study iodide accumulate breast transport across placenta . 4 . Inability tolerate thyroid hormone and/or methimazole preimaging treatment . 5 . History thyroid cancer ( patient could concomitant thyroid cancer metastasis therefore competitively concentrate radioiodides ) 6 . Psychiatric addictive disorder adequately control would preclude obtain informed consent . 7 . Patients heart disease significant cardiac risk factor exclude receive thyroid suppressive therapy avoid precipitate cardiac arrhythmia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>